Interest of tumor to liver ratio 18F-FDG uptake in positron emission tomography for detection of neurofibrosarcoma in neurofibromatosis 1 patients.

P. Combemale(Centre Léon Bérard), S. Pinson(Hôpital Edouard Herriot), L. Allanore(Inserm), F. Giammarile(Hôpital Lyon Sud), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Benoît Bensaïd(Hospices Civils de Lyon), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), Pierre Wolkeinstein(Hôpitaux Universitaires Henri-Mondor), A. Drouet(Hôpital d'instruction des Armées Desgenettes)
Journal of Clinical Oncology
May 20, 2012
10.1200/jco.2012.30.15_suppl.10049
Cited by 1

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978